Table 2.
variable change from baseline to end of study | n* | Mean Pre- Treatment Score | Mean Post- Treatment Score | Mean Change Score | Standard Deviation of Mean Change Score | Median of the Change Score | IQR of the Change Score | pvalue |
---|---|---|---|---|---|---|---|---|
MADRS | 20 | 24.2 ± 3.9 | 10.7 ± 8.5 | 13.5 | 7.9 | 13.5 | 7.0 | <0.0001* |
Hot Flash Scores: 24-hour score | 15 | 9.0 ± 10.3 | 2.5 ± 4.0 | 5.1 | 9.70 | 2.1 | 5.4 | 0.02* |
Daytime hot flash score | 15 | 4.3 ± 4.8 | 1.8 ± 3.6 | 2.0 | 5.0 | 0.9 | 2.9 | 0.05* |
Nighttime hot flash score | 15 | 4.6 ± 5.5 | 0.7 ± 0.8 | 3.2 | 4.9 | 1.1 | 3.1 | 0.002* |
HFRDIS | 15 | 36.9 ± 27.7 | 14.1 ± 24.2 | 22.9 | 27.5 | 20.0 | 44.0 | 0.37 |
indicates significant change from baseline to endpoint (with alpha ≤ 0.05)
N=20, number of participants who started omega-3 fatty acids after the one-week placebo lead in N=15, number of participants who had hot flashes at baseline and could be included in the hot flash analyses